Gene therapy resource program (gtrp): pharmacology and toxicology core laboratory
Ended Awarded Last action
- Contract number
- 75N92023F00001
- Awardee
-
Lovelace Biomedical Research Institute UEI MBT9RXJJ7428
- Awarding agency
-
National Heart Lung and Blood Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $171,742
Award facts
- Contract value 100% obligated
- $171,741.89 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Albuquerque, NM 87108, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Close Out | -$62,736 | |
| Other Administrative Action | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Original award | $234,478 |
About this award
The National Heart, Lung, and Blood Institute (NHLBI) awarded a delivery order to Lovelace Biomedical Research Institute for the Gene Therapy Resource Program (GTRP) Pharmacology and Toxicology Core Laboratory. This cost-plus-fixed-fee contract, valued at $171,741.89, was awarded on September 25, 2023, with a completion date of June 30, 2024. The work will be performed in Albuquerque, New Mexico, and does not utilize a small business set-aside designation. Lovelace Biomedical Research Institute, a not-for-profit preclinical contract research organization, will provide pharmacology and toxicology laboratory services to support the GTRP, which focuses on advancing gene therapy research and development.
This delivery order represents a task order issued against one of Lovelace's existing indefinite delivery/indefinite quantity (IDIQ) contracts with the National Center for Advancing Translational Sciences, valued at $48.8 million for pharmacology studies and animal model development. Lovelace's extensive experience in preclinical research, toxicological assessments, and animal testing makes it well-positioned to deliver the specialized laboratory capabilities required for the GTRP. The contractor has demonstrated substantial expertise supporting federal research needs across multiple therapeutic areas and has successfully executed similar toxicology and pharmacology work for the NHLBI and other federal agencies including the FDA and NIH.
Quick answers
Who was awarded contract 75N92023F00001?
75N92023F00001 was awarded to Lovelace Biomedical Research Institute by National Heart Lung and Blood Institute (National Institutes of Health) on September 25, 2023.
How much is contract 75N92023F00001 worth?
The government has obligated $171,742 on 75N92023F00001.
Is contract 75N92023F00001 an order under another contract?
Yes. 75N92023F00001 is a delivery order under 75N92019D00017, an indefinite delivery contract.
Was contract 75N92023F00001 competed?
The extent of competition for 75N92023F00001 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award